Sonrai and AOA Dx Partner to Accelerate Development of Ovarian Cancer Test
Strategic collaboration leverages Sonrai’s AI-powered platform to support the development of AOA Dx’s multi-omic diagnostic test for ovarian cancer.
AOA Dx Demonstrates High Accuracy in AI-Powered Blood Test for Ovarian Cancer Detection in 1,000 Symptomatic Patient Samples
AOA Dx presented new data at the 2025 AACR Annual Meeting demonstrating high accuracy in early detection of ovarian cancer using its AI-powered multi-omic platform. In collaboration with CU Anschutz Ovarian Cancer Innovations Group (OCIG) and The University of Manchester, the platform achieved AUCs over 90% across approximately 1,000 real-world symptomatic patient samples, outperforming traditional biomarkers like CA125. These results highlight the potential of AOA Dx’s liquid biopsy to aid earlier, more accurate diagnosis and improve outcomes for women worldwide.
AOA Dx Joins BLOODPAC to Accelerate Early Detection of Ovarian Cancer with Liquid Biopsy Innovations
AOA Dx is excited to join the BLOODPAC Consortium, a public-private initiative dedicated to advancing liquid biopsy technologies for cancer detection. Through this partnership, AOA Dx will contribute its expertise in lipidomics and multi-omics to help establish standards for early detection assays, particularly in ovarian cancer. With a commitment to scientific collaboration, AOA Dx plans to share its research on gangliosides, lipids, and proteins, furthering the integration of liquid biopsy into clinical practice.
AOA Dx to Present Latest Research on Tumor-Marker Gangliosides for Early Detection of Ovarian Cancer at International Liquid Biopsy Conference
AOA Dx will showcase its latest research at the International Society of Liquid Biopsy conference (November 23–25, 2024), presenting findings from the study “Identification of Tumor-Marker Gangliosides in Serum for Early-Stage Cancer Diagnosis.” This research underscores the promise of tumor-marker gangliosides (TMGs) as biomarkers for early ovarian cancer detection.
AOA Dx Welcomes Abigail McElhinny, PhD, as Chief Scientific Officer
AOA Dx is announcing the addition of a Chief Scientific Officer, Dr. Abigail McElhinny. Dr. McElhinny comes from a background in leadership in oncology diagnostics. This experience will be transformative for the AOA Dx team.
CEO and Co-Founder Oriana Papin-Zoghbi selected for the TITAN 100 list, recognizing the top 100 CEOs & C-level executives in Colorado
AOA Dx is excited to announce that our CEO, Oriana Papin-Zoghbi, has been selected for the TITAN 100 list. The list highlights Colorado’s most accomplished business leaders in their industry.
AOA Dx secures $17 Million to revolutionize the diagnosis of ovarian cancer with early detection and high accuracy, and to expand their GlycoLocate™ Platform to target a broader range of cancers
AOA Dx is announcing an oversubscribed $17 million round led by Good Growth Capital with participation from leading investors including RH Capital, Y Combinator, Astia Fund, Adaptive Capital Partners, Gore Range Capital, LongeVC, The Helm, VU Venture Partners, and FemHealth Ventures, along with strategic diagnostic investors, including Labcorp Venture Fund. Several funds invested for the second time, underpinning the continuous success of AOA Dx across the last year.
CEO and Co-Founder Oriana Papin-Zoghbi selected for Bloomberg New Economy Catalysts
AOA Dx is excited to announce that our CEO, Oriana Papin-Zoghbi, has been selected for the Bloomberg New Economy Catalysts and will represent the women’s health industry at the Bloomberg New Economy Forum in Singapore.
AOA Dx’s First Peer Reviewed Study Accepted for Publication in Prestigious Journal Frontiers in Oncology
AOA Dx, a biotech company developing a new frontier in early-stage cancer detection through its work in glycolipids, is proud to announce the company’s first published peer reviewed clinical study.
AOA Dx Announces First Patient Enrolled in OVERT Clinical Study Evaluating the AKRIVIS GD™ test for Early Detection of Ovarian Cancer
AOA Dx today announced that the first patient has been enrolled in their OVERT (Ovarian Cancer Early Detection Research) clinical trial. The OVERT trial is a multi-center national trial, the first of its kind in a symptomatic U.S. population. AOA Dx is working with world renowned clinicians and healthcare institutions across the US to bring to market the first test for the early detection of ovarian cancer.